Investment
Features
FeesSafety
Academy
More
Pluang+

Regis Corp beats Q4 2026 EPS estimates with $1.04, showing strong cash flow and stable revenue.

Company Fundamentals
01 Sep 2026
Alex Lavoie
View Source
Bullish
pluang ai news

Regis Corporation reported a strong Q4 2026 with earnings per share of $1.04, far exceeding analyst expectations of $0.17. The company generated $56 million in revenue, slightly down year-over-year but above estimates, supported by a 2.6% sales rise at its Supercuts brand. Regis also maintained positive operating cash flow for the seventh consecutive quarter, demonstrating financial stability. With a P/E ratio of 10.58 and a debt-to-equity ratio of 1.56, the company shows a balanced financial position as it continues to lead in the haircare salon industry.

More News

Medtronic raised to Buy with $100 target after strong Q1 revenue and $700M investment in Heart Tech.

Medtronic raised to Buy with $100 target after strong Q1 revenue and $700M investment in Heart Tech.

Analyst BTIG upgraded Medtronic to a Buy rating and raised its price target to $100, citing strong Q1 FY2027 revenue of $9.76 billion driven by broad demand. The company is investing over $700 million in Heart Tech and Robotics, signaling a focus on ...

Analyst Insights
Bullish
17 minutes ago
UBS keeps Buy on KKR with $123 target as KKR sells USI Insurance for $17B, boosting capital for new investments.

UBS keeps Buy on KKR with $123 target as KKR sells USI Insurance for $17B, boosting capital for new investments.

UBS analyst Michael Brown reaffirmed a Buy rating on KKR & Co. Inc., setting a $123 price target, implying a 15% upside. KKR is selling USI Insurance Services to Aon plc for $17 billion, expected to yield $3.3 billion in after-tax proceeds and $2 bil...

Analyst Insights
Bullish
1 hour ago
Kazia Therapeutics gains analyst confidence as its cancer drug shows strong preclinical results.

Kazia Therapeutics gains analyst confidence as its cancer drug shows strong preclinical results.

Kazia Therapeutics received a Buy rating from analyst firm BTIG, which raised its price target to $40, up from $34, reflecting strong confidence in the company's lead drug, paxalisib. The drug showed a 52% tumor reduction in preclinical colorectal ca...

Analyst Insights
Bullish
1 hour ago
Cheniere Energy gains institutional backing as UBS reaffirms Buy rating, shares near $288.

Cheniere Energy gains institutional backing as UBS reaffirms Buy rating, shares near $288.

Cheniere Energy, a leading U.S. liquefied natural gas producer, saw strong institutional confidence with UBS reaffirming its Buy rating. Major investors like Beacon Pointe Advisors and Rakuten Investment Management increased their stakes, signaling o...

Analyst Insights
Bullish
2 hours ago
Yext beats EPS estimates but misses revenue for 4th quarter; shares rise 8.4%.

Yext beats EPS estimates but misses revenue for 4th quarter; shares rise 8.4%.

Yext reported Q2 earnings with an EPS of $0.21, surpassing analyst estimates of $0.17, resulting in a 23.53% earnings surprise. Despite this, the company's revenue was $111.10 million, slightly below the $111.30 million expected, marking its fourth c...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App